GlassScriptPhysician profile
Cara Panas
NPI 1538550686
$3,721.11
in general payments reported to CMS, 2019-2025
25 companies · $370 in 2025
The $370 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $588 · 2022: $519 · 2023: $1,278 · 2024: $967 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,614.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $891.21 | 2021-2025 | Viewmate, Ensite Precision, Cardiomems |
| Boston Scientific Corporation | $639.48 | 2021-2025 | Watchman Flx, Watchman Access System, Watchman |
| Impulse Dynamics (USA) INC. | $446.23 | 2022-2025 | Optimizer, Optimizer |
| Medtronic, INC. | $262.70 | 2021-2024 | Micra, Cobalt Dr Mri Surescan, Azure Xt Dr Mri Surescan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $245.36 | 2021-2023 | Lifevest |
| Atricure, INC. | $201.23 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $185.99 | 2023-2024 | |
| Pfizer INC. | $172.62 | 2022-2023 | |
| Novo Nordisk INC | $76.77 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $70.55 | 2021-2023 | Camzyos |
| Amgen INC. | $69.21 | 2021-2024 | Repatha |
| Lilly USA, LLC | $62.05 | 2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $60.96 | 2022-2023 | Verquvo |
| Kestra Medical Technology Services, INC. | $55.58 | 2022-2023 | Assure Wcd |
| Baxter Healthcare | $47.67 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $44.73 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $43.51 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $28.04 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $26.84 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $17.84 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $16.19 | 2023 | Opsumit |
| Astellas Pharma US INC | $15.21 | 2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.92 | 2025 | Xifaxan |
| Glaxosmithkline, LLC. | $13.79 | 2025 | Arexvy, Shingrix |
| Kiniksa Pharmaceuticals International, Plc | $13.43 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Panas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.